Compare · MLAB vs TMO
MLAB vs TMO
Side-by-side comparison of Mesa Laboratories Inc. (MLAB) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MLAB and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $232.26B, about 325.9x MLAB ($712.6M).
- Over the past year, MLAB is up 84.6% and TMO is up 28.5% - MLAB leads by 56.0 points.
- MLAB has been more active in the news (13 items in the past 4 weeks vs 10 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 3 for MLAB).
- Company
- Mesa Laboratories Inc.
- Thermo Fisher Scientific Inc
- Price
- $128.13+3.12%
- $628.06-0.13%
- Market cap
- $712.6M
- $232.26B
- 1M return
- +32.24%
- +12.31%
- 1Y return
- +84.59%
- +28.54%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 13
- 10
- Recent ratings
- 3
- 25
Mesa Laboratories Inc.
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The company's Instruments segment designs, manufactures, and markets quality control hardware and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. This segment's products include dialysate meters and calibration solutions, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company's Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Continuous Monitoring segment designs, develops, and markets systems, which are used to monitor various environmental parameters, such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest MLAB
- Director Capone Mark Christopher converted options into 2,784 shares, increasing direct ownership by 81% to 6,213 units (SEC Form 4)
- Director Alltoft Jennifer Sadie converted options into 2,784 shares, increasing direct ownership by 57% to 7,662 units (SEC Form 4)
- Director Ladiwala Shiraz Shabanali converted options into 3,810 shares, increasing direct ownership by 45% to 12,333 units (SEC Form 4)
- Director Hall Shannon converted options into 2,784 shares, increasing direct ownership by 66% to 6,973 units (SEC Form 4)
- Director Tripeny R Tony converted options into 2,784 shares, increasing direct ownership by 44% to 9,082 units (SEC Form 4)
- Director Sullivan John James converted options into 2,784 shares, increasing direct ownership by 16% to 20,618 units (SEC Form 4)
- Director Sullivan John James sold $800,090 worth of shares (7,093 units at $112.80), decreasing direct ownership by 28% to 17,834 units (SEC Form 4)
- President and CEO Kadia Siddhartha bought $800,090 worth of shares (7,093 units at $112.80) (SEC Form 4)
- Director Tripeny R Tony bought $102,321 worth of shares (900 units at $113.69), increasing direct ownership by 17% to 6,298 units (SEC Form 4)
- SEC Form 10-Q filed by Mesa Laboratories Inc.
Latest TMO
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 31 shares, decreasing direct ownership by 0.53% to 5,830 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 20,000 shares at a strike of $309.63 and sold $12,561,823 worth of shares (20,000 units at $628.09) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. sold $7,014,093 worth of shares (11,440 units at $613.12) and exercised 11,440 shares at a strike of $418.32, decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Executive Vice President Shafer Michael D exercised 25,500 shares at a strike of $370.58 and sold $15,300,000 worth of shares (25,500 units at $600.00) as part of a pre-agreed trading plan (SEC Form 4)
- Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
- VP & Chief Accounting Officer Holmes Joseph R. exercised 420 shares at a strike of $309.63 and sold $245,620 worth of shares (420 units at $584.81) (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $2,862,002 worth of shares (4,883 units at $586.12) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. exercised 5,850 shares at a strike of $309.63 and sold $3,393,000 worth of shares (5,850 units at $580.00), decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,616,967 worth of shares (15,000 units at $574.46) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,628,434 worth of shares (15,000 units at $575.23) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)